Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiri...
MediciNova, Inc. is a publicly-traded biopharma...
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
As a leading manufacturer of medical devices and components, Atrion makes a wide r...
As a leading manufacturer of medical devices an...
Adial Pharmaceuticals, Inc. ("the Company") is a clinical-stage biopharmaceutical ...
Adial Pharmaceuticals, Inc. ("the Company") is ...
Akari is a biopharmaceutical company focused on developing inhibitors of acute and...
Akari is a biopharmaceutical company focused on...
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Join the National Investor Network and get the latest information with your interests in mind.